Dublin, May 09, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "BCMA Targeted Therapies, 2017-2030" report to their offering. The "BCMA Targeted Therapies, 2017-2030" report features an extensive study on the current market landscape of B-cell maturation antigen (BCMA) targeted therapies and offers a comprehensive discussion on the future potential of this market. With no commercial products, the market is still in its infancy.However, industry experts have pinned significant hopes on the novel technologies being developed by start-ups/small companies and the research being conducted at academic institutes.
Currently, researchers are actively involved in developing three major types of immunotherapies (classified by product class) targeting BCMA; these are chimeric antigen receptor T-cells (CAR-T cells), bispecific antibodies and antibody drug conjugates (ADCs). Several biopharmaceutical companies have been active in this area since last few years while others have recently stepped in. A number of strategic partnerships have also been inked between various stakeholders to advance R&D activities in this domain. Results of preclinical and clinical studies have demonstrated the potential benefits of this class of therapies; the major highlight being their attractive safety profile. As more molecules undergo clinical validation and eventually get commercialized, we believe the overall interest will continue to rise. In fact, our promising outlook is backed by a strong belief that this novel class of therapies is likely to cater to the current unmet need where the existing treatment modalities are not efficient. The upside could be higher; however, it depends on a favorable market environment, reimbursement practices and regulatory regimes. The prime target indication of these novel molecules is B-cell malignancies, specifically multiple myeloma. BCMA-specific therapies are anticipated to emerge as viable treatment options for such indications. Post initial research on such therapies, many players have entered into collaborations with other stakeholders to fund the clinical and commercial development of their products. Some clinical stage products that have emerged out of such collaborations include bb2121 (bluebird bio/Celgene) and BCMA-CART (Novartis/Abramson Cancer Center of the University of Pennsylvania). The pipeline currently comprises of 23 molecules that are under development for the treatment of a variety of B-cell malignancies. One of the key objectives of this report was to understand the evolution of the current market and to quantify the opportunities laid down by the innovative BCMA targeted programs of both small and big pharma companies. Among other elements, the report provides information on the following: - The current state of the market with respect to key players, phase of development of pipeline products (both clinical and preclinical/discovery) and the type of molecules. - Comprehensive profiles highlighting clinical trial details such as dosage regimens, key preclinical/clinical findings, and future market opportunity for the clinical stage BCMA targeted therapies. - Comparative analysis of the design of clinical trials being conducted for therapies in clinical stages of development. - Various investments and grants received by companies focused in this area supporting their R&D activities. - Partnerships that recently been inked amongst different stakeholders, covering product development/commercialization agreements, research collaborations, license agreements and acquisitions. Key Topics Covered: 1. PREFACE 1.1. Chapter Overview 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. The B-Cell Maturation Antigen 3.2.1. Overview 3.2.2. Mechanism of Action 3.3. Drug Classes for BCMA Targeted Therapies 3.3.1. Bispecific Antibodies 3.3.2. Antibody Drug Conjugates 3.3.3. Chimeric Antigen Receptor T-Cells 3.4. BCMA Targeted Therapies and Research Landscape 3.5. Emergence of BCMA as a Therapeutic Target for the Treatment of Multiple Myeloma 3.5.1. Multiple Myeloma: Introduction and Epidemiology 3.5.2. Multiple Myeloma: Current Treatment Landscape 3.5.3. Multiple Myeloma: Emergence of Novel Targets 3.5.3.1. Immunotherapeutic Targets 3.5.3.2. BCMA: A Promising Antigen 3.6. BCMA Related Targets: A Case Study 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. BCMA Targeted Therapies: Development Pipeline 4.3. BCMA Targeted Therapies: Distribution by Phase of Development 4.4. BCMA Targeted Therapies: Distribution by Type of Molecule 4.5. BCMA Targeted Therapies: Distribution by Type of Developer 4.6. BCMA Targeted Therapies: Distribution by Indication 4.7. BCMA Targeted Therapies: Geographical Landscape 4.8. BCMA Targeted Therapies: Developer Landscape 5. DRUG PROFILES: CLINICAL MOLECULES 5.1. Chapter Overview 5.2. bb2121 (bluebird bio, Celgene) 5.3. CART-BCMA (Novartis, Abramson Cancer Center of the University of Pennsylvania) 5.4. Anti-BCMA CAR-T (National Cancer Institute) 5.5. Anti-BCMA CAR-T (Southwest Hospital, China) 5.6. GSK2857916/J6M0-mcMMAF (GSK, Seattle Genetics) 5.7. AMG 420/BI 836909 (Amgen, Boehringer Ingelheim) 5.8. BCMA Targeted Therapies: Clinical Development Analysis 6. VENTURE CAPITAL INTEREST 6.1. Chapter Overview 6.2. BCMA Targeted Therapies: List of Funding Instances 6.3. Funding Instances: Distribution by Year 6.4. Funding Instances: Distribution by Type of Model 6.5. Leading Players: Distribution by Number of Funding Instances 6.6. Most Active Venture Capital Firms/Investors 7. RECENT COLLABORATIONS 7.1. Chapter Overview 7.2. Partnership Models/Agreements 7.3. BCMA Targeted Therapies: Recent Collaborations 7.4. Recent Collaborations: Distribution by Year 7.5. Recent Collaborations: Distribution by Type of Model 7.6. Recent Collaborations: Distribution by Type of Molecule 7.7. Recent Collaborations: Most Active Companies 8. MARKET FORECAST 8.1. Chapter Overview 8.2. Scope and Limitation 8.3. Forecast Methodology 8.4. Overall BCMA Targeted Therapeutics Market 8.5. BCMA Targeted Therapeutics Market: Drug Specific Forecasts 8.5.1. bb2121 (bluebird bio, Celgene) 8.5.2. CART-BCMA (Novartis, Abramson Cancer Center of the University of Pennsylvania) 8.5.3. Anti-BCMA CAR-T (National Cancer Institute) 8.5.4. Anti-BCMA CAR-T (Southwest Hospital, China) 8.5.5. GSK2857916/J6M0-mcMMAF (GSK, Seattle Genetics) 8.5.6. AMG 420/BI836909 (Amgen, Boehringer Ingelheim) 9. CONCLUSION 9.1. BCMA has Emerged as a Potential Antigen for the Treatment of Multiple Myeloma 9.2. Led by a Number of Technological Advances, CAR- T Therapies are the Current Flag-Bearer 9.3. Even Though Big Pharmaceutical Companies Dominate the Current Space, Several Start-Ups/Small Companies Have Emerged 9.4. Growing Partnerships and Venture Capital Support are Indicative of the Future Potential 9.5. Once Approved, BCMA Targeted Therapies are Poised to Achieve an Accelerated Growth 10. APPENDIX 1: TABULATED DATA 11. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS For more information about this report visit http://www.researchandmarkets.com/research/8l...a_targeted
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Leukemia Drugs
